SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Jefferies Says AstraZeneca Interest in Rhythm Pharmaceuticals Looks Sensible

Jefferies analysts say a potential acquisition would resemble AstraZeneca’s purchase of Alexion on a smaller scale. The Wall Street Journal reported that AstraZeneca made a roughly $10 billion offer for Rhythm Pharmaceuticals.

AZNRYTM

Related stories